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ABSTRACT
Introduction: The use of insulin analogs for the
treatment of type 1 diabetes mellitus (T1DM) is
widespread; however, the therapeutic benefits
still require further evaluation given their
higher costs. The objective of this study was to
evaluate the effectiveness and safety of analog
insulin glargine compared to recombinant DNA
(rDNA) insulin in patients with T1DM in
observational studies, building on previous
reviews of randomized controlled trials
comparing neutral protamine Hagedorn
insulin and insulin glargine.
Methods: A systematic review with a
meta-analysis was performed. The review
included cohort studies and registries available
on PubMed, LILACS, and the Cochrane Central
Register of Controlled Trials (CENTRAL), as well
as manual and gray literature searches. The
meta-analysis was conducted in Review
Manager 5.3 software. The primary outcomes
were glycated hemoglobin (Hb1Ac), weight
gain, and hypoglycemia. Methodological
quality was assessed using the
Newcastle-Ottawa scale.
Results: Out of 796 publications, 11 studies
were finally included. The meta-analysis favored
insulin glargine in HbA1c outcomes (adult
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patients) and hypoglycemic episodes (P\0.05),
but without reaching glycemic control (Hb1Ac
to approximately 7%). The methodological
quality of the studies was moderate, noting
that 45% of studies were funded by
pharmaceutical companies.
Conclusion: Given the high heterogeneity of
the studies, the discrete value presented by the
estimated effect on effectiveness and safety,
potential conflicts of interest of the studies, and
the appreciable higher cost of insulin glargine,
there is still no support for recommending
first-line therapy with analogs. The role of
analogs in the treatment of T1DM could be
better determined by further observational
studies of good methodological quality to
assess their long-term effectiveness and safety,
as well as their cost-effectiveness.
Keywords: Comparative effectiveness research;
Glargine; Insulin; Meta-analysis; Systematic
review; Type 1 diabetes mellitus
INTRODUCTION
Diabetes mellitus (DM) is a chronic metabolic
disease characterized by hyperglycemia due to
changes in insulin secretion or altered action of
insulin, or both. Type 1 DM (T1DM) results
from the destruction of pancreatic beta cells
mediated by cellular autoimmune responses [1].
The treatment of patients with T1DM
consists of repositioning of insulin that is not
produced endogenously. This involves
administering either rapid-acting insulin,
more intermediate or long-acting insulin.
Recombinant DNA (rDNA) insulin and neutral
protamine Hagedorn (NPH), which has an
intermediate-acting time, are typically
first-line choices among the insulins used for
basal glycemic control [2, 3]. Glargine, a
long-acting insulin analog, is used as an
alternative to rDNA insulin. It is a molecule
structurally similar to human insulin and is
developed by modification of the amino acid
sequence, with the aim of prolonging the
duration of the effect and decreasing
intra-individual variability [4].
Metabolic control through active
management of patients with T1DM is based
on three fundamental principles: adequate
food, weight, and glycemic control. These
provide benefits to patients and decrease the
risk of complications [5, 6]. The glycated
hemoglobin (HbA1c) level is the average
glycemic level of an individual over a period
of 2–3 months prior to the test day.
Consequently, it can be used to evaluate
glycemic control and the effectiveness of
current treatments. Glycemia tests indicate
blood glucose levels during testing. Both
these methods are important, since the
information they provide is complementary
and helps to obtain a more global evaluation
of glycemic control. When used together, they
provide safer and more accurate results,
thereby minimizing possible interferences
due to the different technical methodologies
used [7].
T1DM may cause acute and chronic
complications, with hypoglycemia one of the
most important acute complications that can
occur. Microvascular (causing retinopathy,
nephropathy, and neuropathy) and
macrovascular (causing peripheral arterial
disease, carotid disease, and coronary artery
diseases) are the most prevalent chronic
complications [1].
The studies and systematic reviews
performed to date to compare rDNA insulin
with long-acting analogs, including the
authors’ own systematic review of randomized
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controlled trials (RCTs), did not show any
significant differences in the clinical benefits
obtained between the different formulations of
insulin although there can be considerable
differences in costs [3, 8–10]. Published studies
though, including observational studies, have
reported better effectiveness of insulin analogs
compared with human insulin [11–13].
However, the published studies that have
evaluated the performance of different insulins
in non-controlled situations do appear
inconclusive when combined. It is important
to address this confusion given, as mentioned,
the considerable differences in costs that can
occur between the different formulations, for
example, in Brazil, the cost of treating a patient
with insulin glargine is 536% that of treatment
with NPH insulin [3].
Consequently, the aim of this study was to
evaluate the clinical effectiveness of insulin
glargine through a systematic review of
observational studies, which was not addressed
in the authors’ original systematic review [3],
and as a result, help to determine the
performance of long-acting insulins versus
NPH and other insulins in the real-world in
non-controlled situations to provide future
guidance. It is not about assessing the
effectiveness of different interventions to
encourage the prescribing of particular insulin
formulations.
METHODS
This review was conducted in accordance with
the recommendations of the Meta-Analyses and
Systematic Reviews of Observational Studies
(MOOSE) guidelines [14]. This article is based
on previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Study Search
Electronic searches of relevant articles
published until June 2015 in MEDLINE
(PubMed), Latin American and Caribbean
Health Sciences (LILACS), and Cochrane
Library were performed. Various combinations
of terms were used, including terms related to
the disease and type of intervention study
(Table 1).
Hand searching was conducted in the
references of all included studies and the
electronic journal Diabetes Care from 2003
until March 2015. Diabetes Care was chosen as
this is a reputable publication for studies
involving patients with diabetes. The search
for studies in the grey literature was also made
among the theses and dissertations database of
the Coordination for the Improvement of
Higher Education Personnel (CAPES), the
Digital Library of Theses and Dissertations of
the Universidade Federal de Minas Gerais
(UFMG), and ProQuest Dissertations and
database thesis to ensure that the authors did
not miss out important observational studies.
These included lectures, publications and
academic theses, government, congress, books,
and reports.
Eligibility Criteria
Prospective and retrospective cohort studies and
database records of patients with T1DM were
selected. Studies that evaluated the insulin
glargine preparations in comparison with
rDNA insulin to assess the effectiveness and
safety outcomes were included.
Studies that assessed the dosage,
intervention methods, pregnant patients,
clinical protocols, reviews, case reports, animal
studies, in vitro studies, pharmacodynamics
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Table 1 Search strategies
Databases Search strategies Studies
LILACS ((mh:’’Diabetes Mellitus Tipo 1’’ AND ‘‘CetoacidoseDiabe´tica’’) OR (tw:dmid OR dmt1 OR
(diabet$ tip$I) OR (diabet$ tip$1) OR (diabet$ tip$ I) OR (diabet$ tip$ 1) OR (Diabetes
Auto-Imune) OR (C18.452.394.750.124) OR (C19.246.267) OR (C20.111.327) OR
(Diabetes Mellitus Insta´vel) OR (Diabetes Mellitus Insulino-Dependente) OR (Diabetes
Mellitus Dependente de Insulina) OR (Diabetes Mellitus de Inı´cionaJuventude) OR
(Diabetes Mellitus com Tendeˆncia a` Cetose) OR (Diabetes Mellitus de Inı´cioSu´bito)))
AND NOT (mh:’’Diabetes Insı´pido’’ OR tw:(diabet$ insipid$)) AND ((‘‘Insulina’’ OR
‘‘Insulina NPH’’ OR D06.472.699.587.200.500.625 OR D12.644.548.586.200.500.625 OR
D06.472.699.587.200.300.200) OR (tw: glargin$ OR insulin$ OR isofan$ OR nph OR
isophane) OR (ti: glargin$ OR insulin$ OR isofan$ OR nph OR isophane) OR (ab:
glargin$ OR insulin$ OR isofan$ OR nph OR isophane)) AND ((mh:Cohort Studies) OR
tw: Seguimento$ OR tw:coort$ OR (tw:Ana´lise de Coortes) OR tw:incidenc$ OR
(tw:Observational study OR EstudioObservacional OR Estudoobservacional OR
V03.200.650)) AND NOT ((tw: cat$ OR dog$ OR anima$ OR mice OR rat OR rabbits)
OR ab:Prevalence OR ti:Guideline$ OR (ab:Cross-Sectional Study) OR (tw:case report))
381
Medline (via
PubMed)
(((((((((((((((((((Diabetic Ketoacidosis[MeSH Terms]) OR Diabetes Mellitus, Type 1[MeSH
Terms]) OR Diabetes Mellitus, Insulin*Dependent[Text Word]) OR Insulin-Dependent
Diabetes Mellitus[Text Word]) OR Juvenile-Onset Diabetes Mellitus[Text Word]) OR
Type 1 Diabetes Mellitus[Text Word]) OR Sudden-Onset Diabetes Mellitus[Text Word])
OR Diabetes Mellitus, Type I[Text Word]) OR IDDM[Text Word]) OR
Insulin*Dependent Diabetes Mellitus 1[Text Word]) OR Juvenile*Onset Diabetes[Text
Word]) OR Brittle Diabetes Mellitus[Text Word]) OR Ketosis-Prone Diabetes
Mellitus[Text Word]) OR Diabetes, Autoimmune[All Fields] OR Autoimmune
Diabetes[Text Word]) NOT diabetes insipidus[MeSH Terms])))) AND ((((((Insulin,
Isophane[MeSH Terms]) OR Isophane Insulin[Text Word]) OR NPH Insulin[Text
Word]) OR NPH[Text Word]) OR Protamine Hagedorn Insulin[Text Word]) OR
Neutral Protamine Hagedorn Insulin[Text Word]))) AND (((((((glargine[Supplementary
Concept]) OR glargine[Text Word]) OR lantus[Text Word]) OR insulin glargine[Text
Word]) OR HOE*901[Text Word])) OR ‘‘Insulin, Long-Acting’’[Mesh]))) AND
(((‘‘Cohort Studies’’[Mesh]) OR (((cohort$[Text Word]) OR controlled clinical
trial[Publication Type]) OR epidemiologic methods))))
231
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and/or pharmacokinetics studies, studies that
included patients with T2DM, studies that
evaluated concomitant oral therapies with
insulin therapy for patients with T1DM,
studies that evaluated less than or equal to 30
participants as deemed as too small for
meaningful comparisons, or studies that had a
follow-up time of less than 4 weeks were
excluded.
Data Collection and Assessment
of Methodological Quality
The studies found in the electronic databases
were brought together in a single database for
deleting duplicates. The selection was carried
out in three stages by two independent
reviewers and included the analysis of titles,
abstracts, and full texts. Disagreements were
resolved by a third reviewer. Data including
methodological quality, information of
participants, duration of treatment, efficacy,
and safety data were extracted and collected in
duplicate in an Excel form developed for this
purpose and previously tested.
For the assessment of methodological
quality, the authors used the
Newcastle-Ottawa scale for observational
studies [15]. On this scale, each study was
measured in three dimensions: selection of
study groups, comparability of groups, and
determination of the results of interest. The
Table 1 continued
Databases Search strategies Studies
Cochrane #1MeSH descriptor: [Diabetic Ketoacidosis] explode all trees #2MeSH descriptor: [Diabetes
Mellitus, Type 1] explode all trees#3 Diabetes Mellitus, Insulin$Dependent (Word
variations have been searched) #4Insulin-Dependent Diabetes Mellitus (Word variations
have been searched)#5 Juvenile-Onset Diabetes Mellitus (Word variations have been
searched)#6 Type 1 Diabetes Mellitus (Word variations have been searched)#7
Sudden-Onset Diabetes Mellitus (Word variations have been searched)#8 Diabetes
Mellitus, Type I (Word variations have been searched)#9 Insulin$Dependent Diabetes
Mellitus 1 (Word variations have been searched)#10 Brittle Diabetes Mellitus (Word
variations have been searched)#11 Ketosis-Prone Diabetes Mellitus (Word variations have
been searched)#12 Diabetes, Autoimmune (Word variations have been searched)
#13Autoimmune Diabetes (Word variations have been searched)#14 insulin$* depend$
(Word variations have been searched)#15Type 1 diabetes (Word variations have been
searched)#16 {or #1-#15} #17 MeSH descriptor: [Insulin, Long-Acting] explode all
trees#18glargine (Word variations have been searched)#19 lantus (Word variations have
been searched)#20 insulin glargine (Word variations have been searched)#21HOE$901
(Word variations have been searched) #22{or #17-#21} #23 MeSH descriptor: [Insulin,
Isophane] explode all trees#24 Isophane Insulin (Word variations have been searched)#25
NPH (Word variations have been searched)#26 Protamine Hagedorn Insulin (Word
variations have been searched)#27 Neutral rotamineHagedorn Insulin (Word variations
have been searched)#28 {or #23-#27} #34 #28 or #33 #35 #22 and #34 #36#16 and #35
#37 MeSH descriptor: [Cohort Studies] explode all trees #38cohort$ (Word variations have
been searched)#39 epidemiologic methods #40controlled clinical trial:pt (Word variations
have been searched)#41 {or #37-#40} #42#36 and #41
184
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total score is nine, with studies considered of
high methodological quality if above six. In
addition, funding sources were identified to
verify potential sources of bias. The possibility
of publication bias was assessed by analysis of
the funnel plot [16]. It was felt there was
conflict of interest in the study when
somewhere in the text there was commentary
on conflict of interest, it referred to sources of
industry funding, or when there was some link
of the study authors with the pharmaceutical
industry.
Summary of the Findings and Statistical
Analysis
Assessed outcomes included the concentration
of HbA1c, or capillary blood glucose plasma
fasting and episodes of severe hypoglycemia.
Secondary outcomes included the impact on
body mass index (BMI), weight gain, and the
occurrence of adverse reactions.
Data from the studies were combined using
random effects model the Review Manager
(RevMan) software version 5.3. The authors
chose RevMan as this is a typical software
program used for preparing and maintaining
Cochrane Reviews. It was developed through a
continuous process of consultation with its
users and Cochrane methodologists, to
support standards and guidelines for Cochrane
Reviews, and provide analytic methods, access
to ‘online’ help, and validation mechanisms.
RevMan is free to use for authors preparing a
Cochrane Review or for purely academic use.
The results are presented as mean difference
(MD) for continuous variables with a 95%
confidence interval (CI). Analysis with an
I
2
[40% and a P value of Chi square test\0.10
were considered significant heterogeneity.
Sensitivity analyses were conducted to
investigate the causes of any heterogeneity,
excluding a study each time and recorded the
changes in I2 and P values.
RESULTS
Study Inclusion
Seven-hundred and ninety-six publications
were found in the electronic database. After
excluding duplicates, 626 articles were selected
for title assessment, 40 for abstract assessment,
and 18 to be read in their entirety. After
assessing the entire papers, 7 studies were
included and another 4 were added from the
manual check; therefore, a total of 11 studies
were included in the meta-analysis (Fig. 1).
Study Characteristics
From the 11 included observational studies, 1
comprised a database record and 10 were cohort
studies, with 8 being retrospective design
studies and 3 prospective studies. The
follow-up time varied from 6 to 54 months.
Only one study did not have any conflict of
interest, while five stated conflicts of interest.
Three studies did not report any financial
sources, and the remaining four were
supported by pharmaceutical companies
(Table 2). To evaluate the clinical effectiveness
and safety of insulin glargine compared with
rDNA insulin, 11,426 participants were
evaluated from the 11 included studies.
Concerning the patients’ characteristics, the
average age varied between 11 and 57 years.
Four studies assessed adult patients [12, 13, 17,
18], five pediatric patients [19–23], and two
studies assessed both adults and children [24,
25]. The total sample included an average of
55% males. The average time duration of the
disease varied between 2 and 19 years. The
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sample size varied between 43 and 10,469
participants (Table 2).
Methodological Quality
The methodological quality assessment of the
studies using the Newcastle-Ottawa scale
indicated that none of the studies obtained
the maximum score corresponding to nine
stars, while four studies scored eight, four
scored seven, and three had a score of six
(Table 2). Overall, the studies were of
moderate quality. There was no asymmetry in
the funnel chart for the HbA1c outcome,
suggesting an absence of publication bias
(Fig. 2).
Date Synthesis
To evaluate the effectiveness and safety of the
outcomes of the HbA1c values, the insulin total
dosage, severe hypoglycemia, patient weight
gain, and BMI were evaluated. Concerning the
adverse effects night hypoglycemia events and
fasting capillary glycemia, only the results
presented in each study were described since
the data discussed in the studies could not be
combined in the meta-analysis.
Primary Outcomes
The outcome of HbA1c was assessed in two
subgroups: with pediatric patients [19–24] and
with adult patients [12, 13, 17, 18, 24]. The
meta-analysis of the pediatric subgroup of
patients did not show significant differences
between the groups (MD = -0.38; 95% CI
-0.79, 0.04; P = 0.07; I2 = 86%), and the adult
patients subgroup favored insulin glargine
(MD = -0.26; 95% CI -0.48, -0.04; P = 0.02;
I
2
= 53%). In the total combination of
subgroups, the estimate of the effect favored
insulin glargine and the heterogeneity was high
and significant (MD = -0.33; 95% CI -0.54,
-0.12; P = 0.002; I2 = 81%; Table 3; Fig. 3). In
Fig. 1 The process of study selection
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the sensitivity analysis, exclusion of three
studies [17, 20, 24] reduced the heterogeneity,
but did not change the outcome.
Only two studies [19, 21] evaluated the
fasting capillary glycemia, and their results did
not reveal significant differences between the
groups (Table 3).
For the meta-analysis of severe hypoglycemic
episode occurrence, four studies [17, 19, 24, 25]
were included. Data revealed an estimated
difference in the means of -0.58 (95% CI
-0.99, -0.16; P\0.007; I2 = 95%), favoring
analog glargine. In the sensitivity analysis, the
exclusion of Colino et al. [19] decreased the
heterogeneity, without changing the direction
of the outcome (Table 3; Fig. 4).
Analysis of the Subgroup: Follow-up Time
of the Study
The impact on HbA1c levels was assessed
according to the follow-up time of the studies.
Studies considered intermediate [19, 20] revealed
an insignificant difference in the mean values
between the insulin formulations (MD = -0.05;
95% CI -0.92, 0.82; P = 0.91; I2 = 95%). In
studies of a longer duration [12, 13, 17, 18,
21–24], the difference in the means was
estimated at -0.37 (CI -0.61, -0.13; P = 0.003;
I
2
= 70%), thereby favoring insulin glargine. The
consolidation of the above-mentioned groups
revealed an estimated difference in the means of
-0.29, favoring insulin glargine (95% CI -0.51,
-0.08; P = 0.008; I2 = 80%) with a high
heterogeneity pattern (Table 3; Fig. 5). In the
sensitivity analyses, the individual exclusion of
the studies affected neither the direction of the
outcomes nor the significance of the
heterogeneity.
Subgroup Analysis: Conflict of Interest
The impact on HbA1c levels was evaluated in
the subgroups to determine the presence ofT
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conflicts of interest on the findings. The
subgroup without any conflict of interest
[18–23] revealed an insignificant difference
in means (MD = -0.31; 95% CI -0.70, 0.07;
P = 0.11; I2 = 85%). In the subgroup
with conflicts of interest [12, 13, 17, 24],
the difference in the means was estimated
at -0.30 (95% CI -0.59, -0.01; P = 0.05;
I
2
= 41%), favoring insulin glargine.
The total result revealed an estimated
difference in means of -0.31, favoring
insulin glargine (95% CI -0.56, -0.05;
P = 0.02; I2 = 76%) with a high
heterogeneity pattern (Table 3; Fig. 6). In
the sensitivity analyses, the exclusion of the
two studies [20, 24] affected the direction of
the outcome (Table 3; Fig. 6).
Secondary Outcomes
The meta-analysis that evaluated the BMI (in
kg/m2) [10, 11, 13, 15] revealed an insignificant
difference in the means (MD = -0.15; 95% CI
-0.71, 0.40; P = 0.59; I2 = 74%; Table 3). The
sensitivity analyses excluding the study
conducted by Dixon et al. [20] resulted in a
statistical heterogeneity equal to zero, without
changing the direction of the outcome.
Concerning the impact on body weight gain
(in kg), the study results [12, 13, 17, 18, 22, 23]
revealed that there was no significant difference
between the different insulins (MD = -1.38;
95% CI -4.86, 2.10; P = 0.44; I2 = 91%). In the
sensitivity analyses that excluded the study
conducted by Garg et al. [17], a statistical
heterogeneity equal to zero was observed,
Fig. 2 Funnel plot of MD in HbA1c. MD mean difference, SE standard error
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without any change in the direction of the
outcome (Table 3).
For the total dosage of the analog or insulin
(in U/kg/day), the subgroups of pediatric
[19–24] and adult patients [12, 13, 17, 18, 24]
were evaluated. Data revealed that there was no
significant difference in any of the groups
(MD = -0.01; 95% CI -0.12, 0.09; P = 0.83;
I
2
= 88%; and MD = -0.06; 95% CI -0.14,
0.02; P = 0.16; I2 = 72%, respectively). The
total result of the meta-analysis also did not
show a significant difference (MD = -0.03;
95% CI -0.09, 0.04; P = 0.37; I2 = 84%;
Table 3). In the sensitivity analyses of the
adult patient subgroup, exclusion of
Yamamoto-Honda et al. [18] changed the
heterogeneity and the direction of the
outcome, favoring insulin glargine
(MD = -0.09; 95% CI -0.12, -0.06;
P\0.00001; I2 = 0%).
Night-time hypoglycemic events were not
evaluated in this meta-analysis, since the final
studies did not present data that could be
combined statistically. Only three studies
described this outcome [18, 20, 22]. In the
study by Dixon et al. [20], the night
hypoglycemic events in the insulin glargine
group decreased from 12 to 1 during the study
period. However, in the studies by Pa¨iva¨rinta
et al. [22] and Yamamoto-Honda et al. [18], the
results revealed that there was no significant
difference between the different insulins.
Asymptomatic hypoglycemic episodes were
assessed in two studies [20, 21]. In the study by
Dixon et al. [20], the asymptomatic
hypoglycemic events did not present significant
Table 3 Outcomes evaluated in the meta-analysis
Outcomes Studies, n [reference(s)] Participants Estimated effect (95% CI) P value I2 (%)
1.1 HbA1c, % 10 [12, 13, 17–24] 1422 -0.33 (-0.54, -0.12) 0.002 81
Pediatric patients 6 [19–24] 702 -0.38 (-0.79, 0.04) 0.07 86
Adult patients 5 [12, 13, 17, 18, 24] 720 -0.26 (-0.48, -0.04) 0.02 53
1.2 HbA1c, % 10 [12, 13, 17–24] 1280 -0.29 (-0.51, -0.08) 0.008 80
Intermediate duration studies 2 [9, 24] 288 -0.05 (-0.92, 0.82) 0.91 95
Long-duration studies 8 [12, 13, 17, 21–24] 992 -0.37 (-0.61, -0.13) 0.003 70
1.3 HbA1c, % 10 [12, 13, 17 24] 1280 -0.31 (-0.56, -0.05) 0.02 76
With conflict of interest 4 [12, 13, 17, 24] 554 -0.30 (-0.59, -0.01) 0.05 41
7.5 6 [18–23] 726 -0.31 (-0.70, 0.07) 0.11 85
1.4 Severe hypoglycemic,
episodes/person-year
4 [17, 19, 24, 25] 10,967 -0.58 (-0.99, -0.16) 0.007 95
1.5 BMI, kg/m2 4 [13, 19–21] 494 -0.15 (-0.71, 0.40) 0.59 74
1.6 Weight, kg 6 [12, 13, 17, 18, 22, 23] 670 -1.38 (-4.86, 2.10) 0.44 91
1.7 Insulin total dosage,
U/kg/day
10 [12, 13, 17–24] 1350 -0.03 (-0.09, 0.04) 0.37 84
Pediatric patients 6 [19–24] 702 -0.01 (-0.12, 0.09) 0.83 88
Adult patients 5 [12, 13, 17, 18, 24] 648 -0.06 (-0.14, 0.02) 0.16 72
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differences between the insulin glargine and
rDNA insulin groups (2.3± 1.3 and 2.3 ± 1.5,
respectively; P[0.05). In the study by Hathout
et al. [21], the average frequency of
hypoglycemia decreased from 10.6% to 9.2%
after 9 months’ treatment with insulin glargine;
however, it was not statistically significant for all
the groups under study (P = 0.3). The decrease
was more evident in very small children with
pre- and post-glargine hypoglycemic events of
20% and 15%, respectively.
Adverse reactions were assessed in four
studies [13, 18, 19, 24]. In the studies by
Colino et al. [19] and Herwig et al. [24], there
was no significant difference between the
insulin groups. Several patients reported that
they felt more pain during the insulin glargine
injection, but this did not result in the
discontinuation of the treatment [19]. In the
study by Johansen et al. [13], a patient
developed edema and pain in the articulations
immediately after the beginning treatment with
analog glargine, but this did not result in the
suspension of the treatment. The results by
Yamamoto-Honda et al. [18] revealed that
insulin glargine was well tolerated by all the
patients, except for five episodes of failure in the
injection system.
Fig. 3 Glycated hemoglobin meta-analysis: age subgroup.
CI confidence interval, df degrees of freedom, NPH neutral
protamine Hagedorn, SD standard deviation, Method IV
Method based on an iterative estimate and a closed form
confidence interval
Fig. 4 Meta-analysis: episodes of severe hypoglycemia. CI
confidence interval, df degrees of freedom, NPH neutral
protamine Hagedorn, SD standard deviation, Method IV
Method based on an iterative estimate and a closed form
confidence interval
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DISCUSSION
The introduction of analogs as therapeutic
options to treat T1DM presented hope to
millions of patients to obtain greater glycemic
control and prevent both microvascular and
macrovascular complications associated with
hyperglycemia as well as potential injury
caused by hypoglycemic episodes. In this
systematic review with meta-analysis, the
Fig. 5 Glycated hemoglobin meta-analysis: duration of the
study subgroup. CI confidence interval, df degrees of
freedom, NPH neutral protamine Hagedorn, SD standard
deviation, Method IV Method based on an iterative
estimate and a closed form confidence interval
Fig. 6 Glycated hemoglobin meta-analysis: conflict of
interest subgroup. CI confidence interval, df degrees of
freedom, NPH neutral protamine Hagedorn, SD standard
deviation, Method IV Method based on an iterative
estimate and a closed form confidence interval
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authors aimed to assess evidence of the
improved effectiveness and safety of analog
glargine compared to rDNA insulin for the
treatment of patients with T1DM obtained
through observational studies, that is, the real
word [26], thus building on their previous
systematic review of RCTs [3]. It is important
to emphasize that, despite the fact that they
provide robust evidence regarding the efficacy
of interventions, RCTs can have low external
validity, that is, extrapolation of the results to
the community at large including patients with
greater co-morbidities can be limited [27, 28].
The HbA1c evaluation was performed on
1422 participants, comparing insulin glargine
with rDNA insulin, and the result of the
meta-analysis favored insulin glargine;
however, this was without HbA1c control.
Furthermore, for the pediatric subgroup of
patients, the results of the difference in means
did not show any significance. It should be
emphasized that the discrete value of this result,
which involved not achieving ideal control of
HbA1c by the patients, established by the
Brazilian Diabetes Society guidelines, was
lower than 7.5% [29].
In the study by Warren et al. [30], a
systematic review of the efficacy of analog
glargine showed it to be more effective than
rDNA insulin in decreasing fasting blood
glucose, but not for reducing the HbA1c level.
Another outcome assessed in the study
involving 10,967 participants was the
reduction of severe hypoglycemic episodes,
with the findings favoring rDNA insulin [30].
The study by Siebenhofer et al. [31] showed
similar results.
The follow-up period in the reported studies
were divided into short duration (up to
3 months), intermediate (more than 3 months
and up to 6 months), and long (more than
6 months) duration. Short-duration studies
were not included since this parameter reflects
the average glycemic control obtained in the
period from three to 4 months, based on the red
blood cell life cycle [32]. Very short studies of
one-month duration, for example, detected
only 50% of the estimated variation in the
glycemic control [33], a fact that could
introduce bias in the results. The intermediate
duration studies [19, 20] did not demonstrate
significant statistical differences. Most studies
included in this systematic review were of long
duration [12, 13, 17, 18, 21–24] and showed
significant results favoring insulin glargine.
In this systematic review, it was observed
that insulin glargine showed better effectiveness
results compared with rDNA insulin. Vardi et al.
[34] showed similar results in their systematic
review, but the analysis suggested only a modest
clinical benefit using long-acting analogs
instead of intermediate acting insulin
preparations for patients with T1DM. Its effect
was more prominent for the control of night
hypoglycemia [34].
Only one study reported the reason why
insulin glargine treatment was discontinued
[22], which was observed in 9% of the patients
who discontinued treatment before completing
1 year of follow-up. The reasons for interrupting
therapy were night hypoglycemia (n = 2),
failure to reach good glycemic control (n = 3),
patients considered the multiple injection
therapy too laborious (n = 2), and pain
associated with the application (n = 1). After
interruption, two of the patients continued
their treatment with an insulin pump and five
with rDNA insulin.
The authors believe it is worth highlighting
the conflict of interest associated with research,
especially in regards to its ethical and bioethical
aspects. According to Thompson [35], conflict
of interest is a group of conditions in which
professional judgment could be improperly
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influenced by interests such as financial gain.
Conflicts of interest include, for instance,
omission of sponsorship or financial
involvement when publishing a scientific
paper or presenting results at congresses,
avoiding disclosing negative results or
delaying this disclosure with the aim of
protecting a potential market [36].
Publications confirm that financial relations
between the industry, scientific researchers,
and academic institutions can be persuasive
affecting studies and utilization patterns [37,
38] and may influence important aspects of
biomedical research [39]. In this systematic
review when assessing the results of HbA1c,
the subgroup of studies in which there was no
conflict of interest did not demonstrate
significant statistical difference between the
findings from either insulin glargine or rDNA
insulin. On the other hand, in the subgroup
that reported conflicts of interest, the findings
were favorable for insulin glargine (Fig. 6).
The studies selected in this systematic review
and meta-analysis may have been influenced by
publication bias, which is the tendency of the
results published being systematically different
from reality. For example, examination of
clinical trials with a registered protocol in the
registry database ClinicalTrials.gov revealed that
\70% of the studies are eventually published
[40], which may be due to a variety of reasons
[41]. For instance, in a review of published
studies comparing different atypical
antipsychotics, in 90% of the studies
supported by pharmaceutical companies the
reported overall outcome was in favor of the
sponsor’s drug [42]. However, in this systematic
review, the analysis of the funnel chart did not
show asymmetry, suggesting the absence of
publication bias. Having said this, there were
differences in results between the reviewed
studies with and without conflicts of interest
(Fig. 6). In addition, the majority of studies that
showed little precision were generally
performed with small samples and distributed
symmetrically in the largest part of the funnel.
Only the study by Johansen et al. [13] showed
greater precision and was situated in the
narrowest part of the funnel.
This systematic review included only cohort
and patient record studies, which is one of the
limitations of systematic reviews of
observational studies, that is, referring to
selection bias inherent to this type of study
design and to non-controlled confounding
factors. Some studies did not present complete
and accurate information to be included in the
quantitative analysis, thereby affecting the
explanation of the high heterogeneity found
in some comparisons. Differences in the
number of participants between the groups
were also observed as well as during the
follow-up period. Despite this fact,
observational studies have the advantage of
potentially large patient groups and represent
real-world conditions since they are performed
in non-controlled conditions without the strict
confines of RCTs [27].
Another limitation in the interpretation of
the results was the statistical heterogeneity
among the studies found in the meta-analysis.
The small number of studies included in the
comparisons, in addition to the lack of
complete and accurate information in these
studies, hindered the explanation of the sources
of heterogeneity. In the sensitivity analysis, the
inclusion and exclusion of studies in each
comparison did not change the direction of a
majority of the outcomes, with alterations in
heterogeneity. It should be highlighted that the
studies that significantly changed heterogeneity
[17–20, 24, 36] were all sponsored by the
pharmaceutical industry, with the exception of
Yamamoto-Honda et al. [18].
Diabetes Ther
The absence of other published systematic
reviews on the effectiveness and safety of the
different insulins in ‘real-world’ conditions
hinders any comparison with the results from
this review. Typically, systematic reviews
evaluate efficacy studies, that is, patients
enrolled into RCTs, as seen by ours and other
published reviews [3, 8, 31, 34, 43], rather than
including real-world studies. Overall, any
recommendation of the insulin analogs as
first-line therapy should still be considered
with caution, considering the small difference
between the outcomes in the meta-analyses
that have been performed including this study,
potential conflict of interests, and the
appreciable differences in treatment costs in
comparison with therapeutic alternatives that
are available.
CONCLUSIONS
Taking into account the high heterogeneity of
the published studies, the discrete value shown
by assessing the effectiveness and safety
outcomes, the potential conflict of interest of
the included studies, and treatment costs in
contrast to the therapeutic alternatives
available, there is evidence of improved
effectiveness with the analogs. However, these
results need to be treated with caution as there
were differences in findings between studies
where conflicts of interest were reported and
those without conflict of interest. The role of
the analogs in T1DM treatment should be better
determined through more studies with good
methodologies to assess their effectiveness and
safety profile over a long duration as well as
well-conducted economic evaluations focusing
on available therapies. This is particularly
important where there are considerable
acquisition cost differences between available
insulin formulations. In view of these
controversies, the authors are currently
performing their own analysis of the
effectiveness of insulin glargine in real life
amongst a Brazilian population. They hope to
report on this shortly.
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